The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Evaluation Of The Therapeutic Potential Of SFTI-FCQR, A Novel Kallikrein 4-specific Protease Inhibitor
Funder
National Health and Medical Research Council
Funding Amount
$167,303.00
Summary
Prostate and ovarian cancers are on the rise in Australia's ageing population. In previous work, we have studied prostate and ovarian cancer cells that we have engineered to make the protease KLK4. These cells show signs associated with aggressive tumours and in particular may have some of the changes found in cancer cells that spread from their site of origin (metastasize). In this project, we will look at a drug-like molecule that we have designed with the aim of blocking the activity of KLK4.
Expression And Functional Studies On The Novel Ovarian-expressed Serine Protease, Kallikrein 4, In Ovarian Tumorigenesis
Funder
National Health and Medical Research Council
Funding Amount
$410,250.00
Summary
Ovarian cancer is the leading cause of death from gynaecologic malignancies. In Australia, it is the most life-threatening of all gynaecological cancers. The major reason why the death rate has improved little in the last two decades is that ovarian cancer is detected too late and the type of treatment is not very effective. In this research, we are looking at a new protein, called the K4 protein, which belongs to the same family as the PSA enzyme that is used in the PSA test for prostate cancer ....Ovarian cancer is the leading cause of death from gynaecologic malignancies. In Australia, it is the most life-threatening of all gynaecological cancers. The major reason why the death rate has improved little in the last two decades is that ovarian cancer is detected too late and the type of treatment is not very effective. In this research, we are looking at a new protein, called the K4 protein, which belongs to the same family as the PSA enzyme that is used in the PSA test for prostate cancer. Our preliminary findings suggest that K4 is increased in the serous type ovarian cancer tumours so we intend to determine if K4 will be a useful bio-marker for this type of ovarian cancer. We also have made some interesting findings of some novel forms of the K4 protein and gene in ovarian cancer tissues and we intend to characterise these further to see if they might also be useful in detection of this disease. We are also studying the function and localisation of these different forms of K4 in cancer cells, to identify the exact role the enzyme performs in cancer development. These latter studies will help us understand the disease process better and may help us design new treatment approaches.Read moreRead less